A prominent Australian pharmacologist has called for a new approach to treating COVID-19 as hopes fade of finding an effective vaccine or antiviral before the end of the year.
Remdesivir might shorten duration of symptoms in severely ill patients
‘Rushed’ Drug Development that Aims to Refill Pharma Firms’ Pipelines Is Less Likely to Succeed Because of Inter-organizational Friction
When a large pharmaceutical company experiences a drug trial failure and then tries to refill its pipeline by licensing a product created by another firm, such a “rushed innovation” is less likely to bring a product to market than one developed under normal, less hurried conditions. That’s because the hastily drawn licensing agreement between the two organizations leads to friction that drags development work to a halt.
UGA medication experts answer common questions they’re receiving from patients
New Brunswick, N.J. (March 25, 2020) – Stephen K. Burley, director of the RCSB Protein Data Bank headquartered…
Expert on #FDA’s #Expanded Access program: Cost can be a barrier to critically ill patients, healthcare providers, and others seeking to try experimental treatments as a last resort. Dr. Marjorie A. Speers available to comment or participate in inter
Costs related to the expanded access procedure under which critically ill patients can try experimental drugs,…